On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide

ChemBioChem

Volumn 6, Issue 6, 2005, Pages 1104-1109

  Fluiter, Kees ^a   Frieden, Miriam ^b   Vreijling, Jeroen ^a   Rosenbohm, Christoph ^b   De Wissel, Marit B ^a   Christensen, Signe M ^b   Koch, Troels ^b   Ørum, Henrik ^b   Baas, Frank ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Santaris Pharma AS   (Denmark)

Author keywords

Antisense agents; Nucleic acids; Oligonucleotides

Indexed keywords

ALPHA DEXTRO LOCKED NUCLEIC ACID; ANTISENSE OLIGONUCLEOTIDE; BETA DEXTRO AMINO LOCKED NUCLEIC ACID; BETA DEXTRO LOCKED NUCLEIC ACID; BETA DEXTRO THIO LOCKED NUCLEIC ACID; DNA; GAPMER; LOCKED NUCLEIC ACID; LOCKED NUCLEIC ACID DERIVATIVE; MESSENGER RNA; NUCLEOTIDE; OLIGOMER; RNA; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER INHIBITION; CHEMICAL MODIFICATION; CONFORMATION; DNA BINDING; GENE DISRUPTION; GENE KNOCKDOWN; HEART; IN VITRO STUDY; IN VIVO STUDY; LIVER; LUNG; MOLECULAR STABILITY; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; PRIORITY JOURNAL; PROSTATE TUMOR; RNA BINDING; STEREOISOMERISM; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; CELL DIVISION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, RAS; MALE; MICE; NEOPLASMS, EXPERIMENTAL; NUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; RNA; RNA, MESSENGER; STEREOISOMERISM; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 20444479844     PISSN: 14394227     EISSN: None     Source Type: Journal    
DOI: 10.1002/cbic.200400419     Document Type: Article

References (33)

1. S. T. Crooke, Biochim. Biophys. Acta 1999, 1489, 31-44.
2. T. M. Woolf, D. A. Melton, C. G. B. Jennings, Proc. Natl. Acad. Sci. USA 1992, 89, 7305-7309.
3. P. D. Cook, Nucleosides Nucleotides 1999, 18, 1141-1162.
4. a) A. A. Koshkin, S. K. Singh, P. Nielsen, V. K. Rajwanshi, R. Kumar, M. Meldgaard, C. E. Olsen, J. Wengel, Tetrahedron 1998, 54, 3607-3630;
5. b) S. K. Singh, P. Nielsen, A. A. Koshkin, J. Wengel, Chem. Commun. 1998, 455-456;
6. c) S. Obika, D. Nanbu, Y. Hari, J. Andoh, K. Morio, T. Doi, T. Imanishi, Tetrahedron Lett. 1998, 39, 5401-5404.
7. M. Petersen, K. Bondensgaard, J. Wengel, J. P. Jacobsen, J. Am. Chem. Soc. 2002, 124, 5974-5982.
8. J. Wengel in Antisense Drug Technology; Principles, Strategies and Applications. (Ed.: S. T. Crooke), Marcel Dekker, New York, 2001, pp. 339-357.
9. a) J. Kurreck, E. Wyszko, C. Gillen, V. A. Erdmann, Nucleic Acids Res. 2002, 30, 1911-1918;
10. b) D. A. Braasch, Y. Liu, D. R. Corey, Nucleic Acids Res. 2002, 30, 5160-5167;
11. c) M. Frieden, S. M. Christensen, N. D. Mikkelsen, C. Rosenbohm, C. A. Thrue, M. Westergaard, H. F. Hansen, H. Ørum, T. Koch, Nucleic Acids Res. 2003, 31, 6365-6372.
12. For LNA in vivo studies see; a) C. Wahlestedt, P. Salmi, L. Good, J. Kela, T. Johnsson, T. Hökfelt, C. Broberger, F. Porreca, J. Lai, K. Ren, M. Ossipov, A. Koshkin, N. Jakobsen, J. Skouv, H. Oerum, M. H. Jacobsen, J. Wengel, Proc. Natl. Acad. Sci. USA 2000, 97, 5633-5638;
13. b) K. Fluiter, A. L. M. A. ten Asbroek, M. B. De Wissel, M. E. Jakobs, M. Wissenbach, H. Olsson, O. Olsen, H. Oerum, F. Baas, Nucleic Acids Res. 2003, 31, 953-962.
14. For LNA analogues see: a) V. K. Rajwanshi, A. E. Håkansson, M. D. Sørensen, S. Pitsch, S. K. Singh, R. Kumar, P. Nielsen, J. Wengel, Angew. Chem. 2000, 112, 1722-1725;
15. Angew. Chem. Int. Ed. 2000, 39, 1656-1659;
16. b) V. K. Rajwanshi, R. Kumar, M. Kofod-Hansen, J. Wengel, J. Chem. Soc. Perkin Trans. 1 1999, 1, 1407-1414;
17. c) R. Kumar, S. K. Singh, A. A. Koshkin, V. K. Rajwanshi, M. Meldgaard, J. Wengel, Bioorg. Med. Chem. Lett. 1998, 8, 2219-2222;
18. d) S. K. Singh, R. Kumar, J. Wengel, J. Org. Chem. 1998, 63, 6078-6079;
19. e) V. K. Rajwanshi, A. E. Håkansson, B. M. Dahl, J. Wengel, Chem. Commun. 1999, 1395-1396;
20. f) M. Petersen, A. E. Håkansson, J. Wengel, J. P. Jacobsen, J. Am. Chem. Soc. 2001, 123, 7431-7432;
21. g) J. Wengel, M. Petersen, K. E. Nielsen, G. A. Jensen, A. E. Håkansson, R. Kumar, M. D. Sorensen, V. K. Rajwanshi, T. Bryld, J. P. Jacobsen, Nucleosides Nucleotides Nucleic Acids 2001, 20, 389-396;
22. h) M. D. Sørensen, L. Kværnø, T. Bryld, A. E. Håkansson, B. Verbeure, G. Gaubert, P. Herdewijn, J. Wengel, J. Am. Chem. Soc. 2002, 124, 2164-2176.
23. J. B. Hansen, M. Westergaard, C. A. Thrue, B. Giwercman, H. Oerum, Nucleosides Nucleotides Nucleic Acids 2003, 22, 1607-1609.
24. K. Fluiter, A. L. M. A. ten Asbroek, M. van Groeningen, M. Nooij, M. C. G. Aalders, F. Baas, Cancer Res. 2002, 62, 2024-2028.
25. For the anti H-Ras ODN see: a) B. P. Monia, E. A. Lesnik, C. Gonzalez, W. F. Lima, D. McGee, C. J. Guinosso, A. M. Kawasaki, P. D. Cook, S. M. Freier, J. Biol. Chem. 1993, 268, 14514-14522;
26. b) B. P. Monia, J. F. Johston, D. J. Ecker, M. A. Zounes, W. F. Lima, S. M. Freier, J. Biol. Chem. 1992, 267, 19954-19962.
27. A. Aartsma-Rus, W. E. Kaman, M. Bremmer-Bout, A. A. Janson, J. T. Den Dunnen, G. J. Van Ommen, J. C. Van Deutekom, Gene Ther. 2004, 11, 1391-1398.
28. K. E. Nielsen, M. Petersen, A. E. Håkansson, J. Wengel, J. P. Jacobsen, Chem. Eur. J. 2002, 8, 3001-3009.
29. For LNA monomer synthesis see: a) C. Rosenbohm, S. M. Christensen, M. D. Sørensen, D. S. Pedersen, L. E. Larsen, J. Wengel, T. Koch, Org. Biomol. Chem. 2003, 1, 655-663;
30. b) D. S. Pedersen, T. Koch, Synthesis 2004, 4, 578-582;
31. c) D. S. Pedersen, C. Rosenbohm, T. Koch, Synthesis 2002, 2, 802-808.
32. M. J. Graham, S. M. Freier, R. M. Crooke, D. J. Ecker, R. N. Maslova, E. A. Lesnik, Nucleic Acids Res. 1993, 21, 3737-3743.
33. M. K. Bijsterbosch, M. Manoharan, E. T. Rump, R. L. De Vrueh, R. van Veghel, K. L. Tivel, E. A. Biessen, C. F. Bennett, P. D. Cook, T. J. van Berkel, Nucleic Acids Res. 1997, 25, 3290-3296.